National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Drug Information
    Posted: 10/23/2007    Updated: 03/25/2009
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Related pages
Drug Information Summaries

Approval Process for New Cancer Treatments

Access to Investigational Drugs
Dexrazoxane Hydrochloride

This page contains brief information about dexrazoxane hydrochloride and a collection of links to more information about the use of this drug, related research results, and ongoing clinical trials.

US Brand Name(s):Totect
Zinecard
FDA Approved:Yes

Dexrazoxane hydrochloride is approved by the Food and Drug Administration (FDA) to treat severe side effects caused by certain types of chemotherapy. It is used to treat the following:

  • Extravasation caused by intravenous anthracyclines. Extravasation occurs when injected drugs leak out of the vein, into surrounding tissue. This can cause redness, pain, and swelling, and may damage the tissue. This use is approved for the Totect brand of dexrazoxane hydrochloride.
  • Cardiac (heart) side effects caused by doxorubicin in women being treated for metastatic breast cancer. Dexrazoxane hydrochloride helps make the side effects happen less often and makes them less severe when they do occur. It is used only in women who have already received high doses of doxorubicin and continue to be treated with it. This use is approved for the Zinecard brand of dexrazoxane hydrochloride.
Information from the FDA

FDA Approval for Dexrazoxane Hydrochloride - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.

Information from the NCI

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trial Results: Heart Risks of Doxorubicin Higher Than Previously Reported (05/28/2003) - Important clinical trial results for this drug, background information, and how the trial was done.

Information from the National Library of Medicine (NLM)

MedlinePlus Information on Dexrazoxane Hydrochloride - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Clinical Trials

Clinical Trials for Dexrazoxane Hydrochloride - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.

Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.


Back to TopBack to Top


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov